Real-World data on ripretinib for advanced GIST: what patients experience
NCT ID NCT06619275
First seen Dec 08, 2025 · Last updated Apr 28, 2026 · Updated 17 times
Summary
This study looked at 10 adults with advanced gastrointestinal stromal tumor (GIST) who had already tried three or more treatments. Researchers observed how ripretinib affected their quality of life and disease control in routine German clinics. The goal was to gather real-world information, not to test a new drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIST - GASTROINTESTINAL STROMAL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Praxis für interdisziplinäre Onkologie und Hämatologie
Freiburg im Breisgau, Germany
Conditions
Explore the condition pages connected to this study.